Christie Teigland’s Post

Just released! New study from Inovalon and Genentech finds racial disparities in emergency department visits for liver cancer care. Research reveals how social drivers of health influence higher rates of emergency department utilization for Black and Hispanic hepatocellular carcinoma patients. Read more: https://ow.ly/xxhH50SnIip

What are the variations in Medicare Advantage plans and their impact on patient outcomes? Join us for our #LinkedInLive chat with Christie Teigland and Boris Vabson, who have been leading the Inovalon-Harvard Medical School Medicare research collaboration. They will share insights into how different plan design features influence enrollment, address socioeconomic-related health disparities, and impact healthcare utilization. Don't miss this opportunity for a quick overview of the fourth and final study of the Inovalon and Harvard collaboration on Medicare Advantage plans. Here's how to join our Linkedin Live chat. Visit our Linkedin profile on Tuesday, June 18 at 1:30 pm ET. When we go live, our profile background photo will automatically change to display the livestream. You can view the stream on our profile or click on the stream to enter theater mode. #MedicareAdvantage

On the lighter side, this made me laugh hard, especially the dot matrix printer. And accurately represents what we all know is our need for better patient experience! https://lnkd.in/ekRc4T2s

What if you could peek into groundbreaking research that could transform diabetes treatment for millions? Inovalon and the Pharmacy Quality Alliance (PQA) are doing just that by analyzing the impact of the Medicare insulin cost cap. Leveraging our industry-leading, nationally representative primary source dataset, this study delves into patient persistence in basal insulin therapy before and after the cost cap. The results could revolutionize access to treatment for Medicare Advantage beneficiaries. Christie Teigland, PhD, VP of Research Science and Advanced Analytics at Inovalon, shares, “This partnership underscores our dedication to leveraging advanced analytics to enhance healthcare outcomes and bridge disparities in treatment access for all Americans battling diabetes.” Read more about this pivotal study. https://ow.ly/wPOV50Sijnl #HealthcareInnovation #DiabetesCare #AdvancedAnalytics

What are the variations in Medicare Advantage plans and their impact on patient outcomes? Join us for our #LinkedInLive chat with Christie Teigland and Boris Vabson, who have been leading the Inovalon-Harvard Medical School Medicare research collaboration. They will share insights into how different plan design features influence enrollment, address socioeconomic-related health disparities, and impact healthcare utilization. Christie and Boris will provide a quick overview of the fourth and final study of the Inovalon and Harvard collaboration on Medicare Advantage plans. https://ow.ly/rOvm50Sa8Um Here's how to join our Linkedin Live chat. Visit our Linkedin profile on Tuesday, June 18 at 1:30 pm ET. When we go live, our profile background photo will automatically change to display the livestream. You can view the stream on our profile or click on the stream to enter theater mode.

Thrilled to share that Dr. Rochelle Walensky, the former CDC director, will be a keynote speaker at Empower! With her extensive background in clinical trial research, public health policy, and patient care, her insights will be invaluable. Join us to learn from a healthcare powerhouse: https://ow.ly/UWc830sE7fh #InovalonEmpower24

Congratulations to our Insights team who brought home Medtech Breakthrough's "Best Data Visualization Solution" of 2024 award for the SDOH Market Insight solution. We've combined the largest primary source patient dataset, 50 SDOH measures, and robust analytics to create a cutting-edge SaaS solution. Offering detailed data and dynamic visualizations, the #SDOH Market Insights solution empowers life sciences teams to enhance customer engagement, broaden patient access, and boost therapy adherence, all while advancing health equity. Learn more about the impact of this award-winning solution and hear from industry experts Mark Rodgers and Christie Teigland about its game-changing capabilities: https://ow.ly/svjW50RCcqR

BREAKING: Court says Tukey is dookie 💩.The #MedicareAdvantage industry buzzes over SCAN’s victory over #CMS on #StarRatings. The court ruled CMS misapplied its new formulas for calculating SCAN’s Star Rating, which dropped from 4.5 to 3.5 Stars, costing the plan $250 million in quality bonus payments. In what promises to be a health law firm Full Employment Act, dozens of plans which suffered the same result as SCAN are now assessing their legal options. It’s too soon to say if this news will force CMS to revise the Stars rules, especially the dreaded Tukey Outlier. Stay tuned. Implications of this could be huge for the industry.

I'm excited to share that the Pharmacy Quality Alliance, in partnership with Inovalon, is evaluating the impact of the Medicare out-of-pocket cost cap for insulin on persistence to basal insulin. As of January 1, 2023, Medicare beneficiaries who receive insulin covered under Medicare Part D pay no more than $35 in out-of-pocket costs for a month’s supply. This analysis will provide early insights into the impact of the insulin price cap on patient persistence, and will use the PQA-endorsed Persistence to Basal Insulin(PST-INS) health plan performance measure to compare measure rates before and after the implementation of the cost cap in a large nationally representative sample of Medicare Advantage beneficiaries. Given the cost and burden of diabetes for patients and our health care system, this is an important opportunity to evaluate the correlation between recently enacted policy aimed at improving access to basal insulin and its real-world effects. This project is supported by Eli Lilly and Company and Novo Nordisk, and results from the analysis are expected in early 2025.